.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a median follow-up of 11 months, individuals with metastatic intestinal cysts that obtained biomarker-matched treatments based on circulating tumor DNA profiling revealed a more significant medical advantage than those obtaining incomparable therapy.